Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer

Journal of Surgical Oncology

Volumn 110, Issue 8, 2014, Pages 982-988

  Ooki, Akira ^a   Akagi, Kiwamu ^a   Yatsuoka, Toshimasa ^a   Asayama, Masako ^a   Hara, Hiroki ^a   Takahashi, Akemi ^a   Kakuta, Miho ^a   Nishimura, Yoji ^a   Yamaguchi, Kensei ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Adjuvant chemotherapy; BRAF; Colorectal cancer; MSI

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; OXALIPLATIN; B RAF KINASE; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BRAF GENE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MONOTHERAPY; ONCOGENE; TREATMENT OUTCOME; TREATMENT PLANNING; WILD TYPE; AGED; COLORECTAL NEOPLASMS; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS;

AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84910125528     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23755     Document Type: Article

References (40)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
2. Kuebler JP, Wieand HS, O'Connell MJ, et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25:2198-2204.
3. Haller DG, Tabernero J, Maroun J, et al.: Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-1471.
4. Schmoll HJ, Van Cutsem E, Stein A, et al.: ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479-2516.
5. Meyers M, Wagner MW, Hwang HS, et al.: Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001;61:5193-5201.
6. Bertagnolli MM,Niedzwiecki D, Compton CC, et al.: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and leukemia group B protocol 89803. J Clin Oncol 2009; 27:1814-1821.
7. Jover R, Zapater P, Castells A, et al.: The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-373.
8. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349: 247-257.
9. Sargent DJ, Marsoni S, Monges G, et al.: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil?based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-3226.
10. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618.
11. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
12. Rajagopalan H, Bardelli A, Lengauer C, et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch?repair status. Nature 2002;418: 934.
13. Wang L, Cunningham JM, Winters JL, et al.: BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-512.
14. Gavin PG, Colangelo LH, Fumagalli D, et al.: Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18:6531-6541.
15. Lochhead P, Kuchiba A, Imamura Y, et al.: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-1156.
16. Ogino S, Shima K, Meyerhardt JA, et al.: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
17. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60- 00 trial. J Clin Oncol 2010;28:466-474.
18. French AJ, Sargent DJ, Burgart LJ, et al.: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008;14:3408-3415.
19. NCCN Clinical Practice Guildelines in Oncology, Colon Cancer. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp 2014; version 3.
20. Gunderson LL, Jessup JM, Sargent DJ, et al.: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28:264-271.
21. Gao P, Song YX, Wang ZN, et al.: Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer- Analysis of the surveillance, epidemiology, and end results (SEER) database. BMC Cancer 2013;13:123.
22. Haller DG, Catalano PJ, Macdonald JS, et al.: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089. J Clin Oncol 2005; 23:8671-8678.
23. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
24. Lembersky B, Wieand H, Petrelli N, et al.: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from national surgical adjuvant breast and bowel project protocol C-06 J Clin Oncol 2006;24:2059-2064.
25. Yoshida M, Ishiguro M, Ikejiri K, et al.: S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol. 2014;Jun 18 [Epub ahead of print].
26. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
27. Ishikubo T, Nishimura Y, Yamaguchi K, et al.: The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. Cancer Lett 2004;216:55-62.
28. Halling KC, French AJ, McDonnell SK, et al.: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-1303.
29. Laiho P, Launonen V, Lahermo P, et al.: Low-level microsatellite instability in most colorectal carcinomas. Cancer Res 2002;62: 1166-1170.
30. Asaka S, Arai Y, Nishimura Y, et al.: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes'A to Dukes'B. Carcinogenesis 2009;30:494-499.
31. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al.: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-2402.
32. Samowitz WS, Sweeney C, Herrick J, et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-6069.
33. Koopman M, Kortman GA, Mekenkamp L, et al.: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-273.
34. Ashktorab H, Smoot DT, Carethers JM, et al.: High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res 2003;9:1112-1117.
35. Soliman AS, Bondy ML, El-Badawy SA, et al.: Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. Br J Cancer 2001;85:1037-1046.
36. Kim SH, Shin SJ, Lee KY, et al.: Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: A retrospective cohort study. Ann Surg Oncol 2013;20:3407-3413.
37. Han SW, Lee HJ, Bae JM, et al.: Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 2013;132:2209-2216.
38. Ionov Y, Peinado MA, Malkhosyan S, et al.: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561.
39. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
40. Chen D, Huang JF, Liu K, et al.: BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: A systematic review and meta-analysis. PLoS One 2014;9:e90607.